Risk communication about high-dose MDMA: Impact of a hypothetical drug alert on future MDMA use.

Introduction: Despite high-dose 3,4-methylenedioxymethamphetamine (MDMA) drug alerts being distributed, no research has been conducted as to changes in use in response. This study aimed to determine if: (i) high-dose MDMA drug alerts, and (ii) varied descriptions of dose, effects and actions to reduce harm were associated with intentions to reduce the initial MDMA dose in a hypothetical scenario.

Methods: Australians who used MDMA pills/capsules in the past year completed an online survey.

A phase 3 randomised double-blind placebo-controlled trial of mirtazapine as a pharmacotherapy for methamphetamine use disorder: a study protocol for the Tina Trial.

Background: There are no approved pharmacotherapies for methamphetamine use disorder. Two preliminary phase 2 randomised controlled trials have found mirtazapine, a tetracyclic antidepressant, to be effective in reducing methamphetamine use. The proposed Tina Trial is the first phase 3 placebo-controlled randomised trial to examine the effectiveness and safety of mirtazapine as an outpatient pharmacotherapy for methamphetamine use disorder.